|
MO2-2 Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen) |
|
|
|
Titel: |
MO2-2 Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen) |
Auteur: |
Kato, Terufumi Endo, Masahiro Saito, Yoshinobu Baba, Tomohisa Tsujino, Kayoko Shibuya, Keiko Fujiwara, Yutaka Kenmotsu, Hirotsugu Oikado, Katsunori Sakamoto, Kei Nii, Masahiro Hotta, Mariko Noda, Yuka Tokimoto, Toshimitsu Sakai, Fumikazu Kusumoto, Masahiko |
Verschenen in: |
Annals of oncology |
Paginering: |
Jaargang 34 () nr. S3 pagina's S1395 |
Jaar: |
2023 |
Inhoud: |
|
Uitgever: |
European Society for Medical Oncology |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|